facebook pixel
chevron_right Trending_Health
transparent
FDA Approves Final Trials of MDMA as Post-Traumatic Stress Disorder Treatment
On 29 November 2016, the Food and Drug Administration opened the door to new exploration of treating post-traumatic stress disorder using the mood-altering drug methylenedioxymethamphetamine. If the trials are successful, MDMA could be an available treatment option as early as 2021. MDMA is currently classified as a Schedule 1 drug by the US Drug Enforcement Administration, meaning that it currently has no listed therapeutic use and a large risk of abuse.

Want to stay updated ?

x

Download our Android app and stay updated with the latest happenings!!!


50K+ people are using this